The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA
- Monday, April 11, 2022, 9:20
- Environment
- Add a comment
SHANGHAI, April 11, 2022 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the…
About the Author
adminasapcorp has written 41558 stories on this site.